J Clin Oncol 2005,23(5):1011–1027.PubMedCrossRef 8. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, et al.: Association between HER-2/neu and vascular endothelial growth www.selleckchem.com/products/mk-5108-vx-689.html factor expression predicts clinical outcome in primary breast cancer patients.

Clin Cancer Res 2004,10(5):1706–1716.PubMedCrossRef 9. Sledge GW Jr: Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002,29(3 Suppl 11):104–110.PubMedCrossRef 10. de Castro Junior G, Puglisi F, de Azambuja E, El Saghir NS, Awada A: Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the “”do ut des”" paradigm). Crit Rev Oncol Hematol 2006,59(1):40–50.PubMedCrossRef 11. Jain RK: Clearing the smoke on nicotine and angiogenesis. Nat Med 2001,7(7):775–777.PubMedCrossRef 12. Gasparini G, Longo R, Fanelli M, Teicher BA: Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005,23(6):1295–1311.PubMedCrossRef

13. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL: Independent review of E2100: a phase III Angiogenesis inhibitor trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009,27(30):4966–4972.PubMedCrossRef 14. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, et al.: Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2011, in press. 15. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. The New England journal of medicine 2007,357(26):2666–2676.PubMedCrossRef 16. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I,

Lipatov O, Perez E, Yardley D, Zhou X, Phan S: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 2009,27(15S):1005. (-)-p-Bromotetramisole Oxalate 17. GSK1120212 in vivo Pignon JP, Hill C: Meta-analyses of randomised clinical trials in oncology. The lancet oncology 2001,2(8):475–482.PubMedCrossRef 18. Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nistico C, Terzoli E, Cognetti F, et al.: Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?: a meta-analysis of 20 phase 3 trials. Cancer 2007,110(3):525–533.PubMedCrossRef 19. Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine 1998,17(24):2815–2834.PubMedCrossRef 20.